Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma
IDH1- mutant CCA is characterized by an increased abundance of M2-like TAMs. Targeting CCL2 remodels the tumor immune microenvironment and improves outcomes in preclinical models of IDH1 -mutant CCA, highlighting the role of myeloid-targeted immunotherapies in the treatment of this cancer.
Authors
- Soren Charmsaz (ORCID: https://orcid.org/0000-0002-9148-9870)
- Saumya Maru (ORCID: https://orcid.org/0000-0002-9548-3505)
- Daniel J. Zabransky (ORCID: https://orcid.org/0000-0002-8184-3346)
- Emma Kartalia (ORCID: https://orcid.org/0009-0000-6891-0498)
- William Brian Dalton (ORCID: https://orcid.org/0000-0002-1314-0534)
- Jae W. Lee (ORCID: https://orcid.org/0000-0002-0735-5707)
- Sebastià Franch‐Expósito (ORCID: https://orcid.org/0000-0002-4542-1701)
- Marina Baretti (ORCID: https://orcid.org/0000-0003-0125-2405)
- Yash Chhabra (ORCID: https://orcid.org/0000-0003-2883-4675)
- Elizabeth M. Jaffee (ORCID: https://orcid.org/0000-0003-3841-6549)
- Noushin Rastkari (ORCID: https://orcid.org/0000-0002-6321-3586)
- Michael S. Davis (ORCID: https://orcid.org/0000-0002-5101-4432)
- Sara E. Young (ORCID: https://orcid.org/0009-0005-7534-0952)
- James M. Leatherman (ORCID: https://orcid.org/0000-0002-1721-2128)
- Mark Yarchoan (ORCID: https://orcid.org/0000-0003-4401-0748)
- Kiyoko Oshima (ORCID: https://orcid.org/0000-0002-3357-6247)
- Martin Kang (ORCID: https://orcid.org/0000-0003-2209-5365)
- Nilofer S. Azad
Institutions
- Fox Chase Cancer Center (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Tempus Labs (United States) (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Hepatology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1097/hep.0000000000001185
- Citations
- 7
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Massachusetts General Hospital
- Cholangiocarcinoma Foundation
- Moonshot Research and Development Program
- Cancer Moonshot